At a glance
| Molecular size | Six amino acids |
|---|---|
| Cosmetic context | Matrix-related skin appearance |
| Important derivative | Cyclized hexapeptide-9 / CHP-9 |
| Delivery research | Ionic-liquid combination systems |
| Main limitation | Modified systems are not interchangeable |
Overview
The name hexapeptide-9 identifies a particular six-residue cosmetic peptide rather than any six-amino-acid ingredient. Its research context includes collagen-related signaling and efforts to overcome peptide instability and poor skin delivery. Two important distinctions shape the evidence: cyclizing a molecule changes its structure, while adding a penetration-enhancing vehicle changes its exposure. A positive study of either modified system does not establish that a conventional cream containing the unmodified peptide will perform similarly. The complete ingredient specification and formulation therefore matter. Strong-looking trial titles need to be read alongside the comparator, study duration, and exact molecule used.
How it works
The proposed cosmetic action concerns extracellular-matrix support and cellular responses associated with skin aging. Delivery research has combined linear hexapeptide-9 with a GABA/lactic-acid ionic-liquid system, while another program cyclized the peptide to improve stability and permeability. These modifications are part of the experimental intervention. Their effects cannot be separated from the peptide by assuming that all formulations share the same biological exposure.
The randomized trial studied a derivative
A 2025 randomized, blinded trial compared a cyclized hexapeptide-9 serum with a retinol serum and vehicle over 56 days. Several wrinkle measures favored the cyclized formulation. The tested compound was CHP-9, not ordinary linear hexapeptide-9, and the chosen retinol comparator does not represent every clinical retinoid regimen.
Supporting sources [1]
The delivery study answers another question
A separate study evaluated hexapeptide-9 with an ionic-liquid penetration enhancer in laboratory, animal, and clinical experiments. It supports investigation of that combined platform. Improved delivery in the system cannot establish the penetration or efficacy of an unrelated moisturizer that lists hexapeptide-9 without the same technology.
Supporting sources [2]
Assess the actual finished product
Cosmetic status is not FDA drug approval. Stability, irritation, and absorption can change when a peptide is cyclized or a barrier-modifying ingredient is introduced. Evidence for ordinary linear hexapeptide-9 remains limited until independent studies directly evaluate the exact formulation and appearance-related claims being considered.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic collagen-related hexapeptide.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Cyclized hexapeptide-9: randomized active- and vehicle-controlled cosmetic trial ↗Clinical trial source · Checked 2026-10-27
- Hexapeptide-9 with an ionic-liquid delivery system: experimental and clinical work ↗Original research · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27